New Frontiers in the Discovery and Treatment of Thrombosis

Organizer(s): Jane E. Freedman, Bruce Furie and Dietmar Seiffert

Sponsored by Bayer HealthCare Pharmaceuticals

For important information on the coronavirus, please click here

Summary of Meeting:

During the last several decades, there has been unprecedented growth in the fundamental understanding of coagulation and platelet function. The logical evolution of these discoveries has been the development of a wide array of therapies targeting platelet receptors and pathways within coagulation to treat thrombotic diseases. Although clearly successful, the evolution of these agents is at a crossroads due to limitations and questions including hemorrhage and pleiotropic effects. The goal of this symposium is to explore new discoveries in thrombosis and consider their potential for translation relative to existing/developing therapies. This symposium will focus on: 1) Understanding how fundamental mechanisms regulating vascular disease risk factors and genetics modulate coagulation; 2) Investigating how these processes influence platelet-dependent thrombosis and vessel wall interactions; and 3) Determining how the evolution of treatments for thrombosis has led to a new appreciation of the complex interactions between coagulation and thrombosis, and how this may guide the use of new and existing therapies. This meeting will bridge clinical and basic investigators to discuss a rapidly evolving field. The goal is to gain a greater appreciation of the novel discoveries in the areas of vascular occlusion, the treatment of thrombosis and the minimization of risk.

Scholarship Deadline: October 9 2013

Discounted Abstract Deadline: October 9 2013

Abstract Deadline: October 31 2013

Discounted Registration Deadline: November 25 2013

Abstacts when book is in proofing process

Keystone Symposia thanks our Sponsor(s) for generously supporting this meeting:

We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:

Pfizer Inc.

We gratefully acknowledge the generous grant for this conference provided by:

National Heart, Lung, and Blood Institute (NHLBI)
Grant No. 1R13HL120495-01
The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:

Click here to view more of these organizations

Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:

Click here to view more of these organizations